Best practices for the Multidisciplinary Management of NHL using Antibody Therapeutics
Pre-test

Questions marked with a * are required

100%

Contact Information

First Name

Last Name

Email Address

In the phase 3 POLARIX study, the role of polatuzumab vedotin was supported in the following subset of patients:

Untreated DLBCL and IPI score of 0 or 1

Untreated DLBCL and IPI score >1

Relapsed/refractory DLBCL as second line therapy

Relapsed/refractory DLBCL after two prior lines of therapy

Which statement regarding the findings of the phase 2 LOTIS-2 trial investigating loncastuximab tesierine in patients with R/R DLBCL is true?

Approximately 1/3 of patients in the treatment arm of the study achieved CR.

Approximately 1/2 of patients in the treatment arm of the study achieved CR.

Approximately 1/3 of patients in the treatment arm of the study who achieved CR were event free for ≥2 years

Approximately 1/2 of patients in the treatment arm of the study who achieved CR were event free for ≥2 years

Alexander is a 53-year-old man with primary refractory non-GCB DLBCL who was previously treated with R-CHOP, followed by axi-cel. He now presents with worsening lymphadenopathy. You confirm relapse with excisional biopsy. What is the next best step for this patient?

Chemotherapy and autologous transplant

Field radiation

Mosunetuzumab

Glofitamab

Martin is a 64-year-old male who has primary refractory advanced stage GCB DLBCL. He has previously been treated with R-DA-EPOCH, followed by Pola-BR and axi-cel. You determine now that he may be a viable candidate for a bispecific antibody. When counseling the patient about adverse events related to treatment with this class of agents, your discussion should include which of the following?

The patient may expect low frequency of grades 1-4 CRS events

The patient may expect low frequency of grade 3+ CRS events

The patient may expect high frequency of grades 1-4 ICANS events

The patient may expect high frequency of grades 3+ ICANS events

Powered by QuestionPro

Loading...